证券研究报告|港股公司点评报告 [Table_Date] 2025 年 08 月 28 日 [Table_Title] 上半年业绩超预期，幸运咖加速门店布局 [Table_Title2] 蜜雪集团(2097.HK) | [Table_DataInfo] 评级： | 增持 | 股票代码： | 2097 | | --- | --- | --- | --- | | 上次评级： | 增持 | 52 周最高价/最低价(港元)： | 568.0/290.0 | | 目标价格(港元)： | | 总市值(亿港元) | 1,747.76 | | 最新收盘价(港元)： | 460.4 | 自由流通市值(亿港元) | 694.67 | | | | 自由流通股数(百万) | 150.88 | [Table_Summary] 事件概述 2025H1，公司实现收入 148.75 亿元/+39.3%，归母净利润 26.93 亿元/+42.9%。 分析判断 ► 外卖大战+持续推新，驱动单店商品销售收入增长 今年 4 月份以来，京东、美团、饿了么等平台相继加大外卖补贴力度，现制茶饮和咖啡行业充分受益；同时， 公司持续推新，提升产品力，蜜雪冰城 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company continues its "big product" strategy, which is expected to drive product optimization and margin improvement, although the increase in sales expenses may impact net profit margins [5] - The company has seen revenue growth driven by e-commerce and group buying channels, with key products like ergonomic pillows and ice cream quilts enhancing brand influence [3] - The gross margin has improved, but net profit margin has declined due to rising sales expenses [4] Summary by Sections Financial Overview - For the first half of 2025, the company's revenue, net profit attributable to the parent, and net profit excluding non-recurring items were 1.921 billion, 141 million, and 103 million CNY, respectively, showing year-on-year growth of 6.40%, a decline of 3.38%, and a decline of 21.52% [2] - In Q2 2025, the revenue was 995 million CNY, with net profit attributable to the parent at 51 million CNY, reflecting year-on-year growth of 11.74% but a decline in net profit of 2.65% [2] Product Strategy - The company has focused on niche markets, developing core products like ergonomic pillows and ice cream quilts, which have driven overall category sales [3] - The "big product" strategy leverages scale, high exposure, and continuous iteration to build a competitive moat and enhance brand recognition [3] Margin Analysis - In H1 2025, the gross margin was 43.88%, an increase of 2.01 percentage points year-on-year, while the net margin was 7.34%, a decrease of 0.75 percentage points [4] - The increase in sales expenses by 3.8 percentage points has primarily contributed to the decline in net profit margin [4] Investment Recommendations - The company is expected to maintain its revenue forecasts for 2025-2027 at 4.401 billion, 4.725 billion, and 5.079 billion CNY, with net profit forecasts of 381 million, 402 million, and 427 million CNY, respectively [5] - The projected earnings per share (EPS) for 2025-2027 are 1.45, 1.53, and 1.63 CNY, with corresponding price-to-earnings (PE) ratios of 12.2, 11.6, and 10.9 [5]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights that the company is continuously advancing its brand overseas and transforming its IP, which brings new vitality to its operations [1] - The company is transitioning from a stationery leader to a cultural and creative giant, with a focus on upgrading traditional business products and channels to enhance volume and price [9] - The company is actively exploring overseas markets and adapting its business model accordingly [8] Summary by Sections Event Overview - In the first half of 2025, the company achieved revenue of 10.809 billion yuan, a year-on-year decrease of 2.19%, and a net profit attributable to shareholders of 557 million yuan, down 11.97% year-on-year [2] Analysis and Judgments - **By Channel**: - The company’s office supplies segment (KeliPu) generated revenue of 6.129 billion yuan in the first half of 2025, a slight increase of 0.15% year-on-year, focusing on MRO industrial products and marketing gifts [3] - The retail segment (including Jiuwu) achieved revenue of 779 million yuan, up 6.98% year-on-year, with Jiuwu contributing 756 million yuan, a growth of 9.49% [3] - The technology segment reported revenue of 556 million yuan, a growth of 15.14% year-on-year, driven by the acceleration of new channel business development [4] - **By Product**: - Sales figures for various product categories in the first half of 2025 were as follows: writing tools (1.136 billion yuan), student stationery (1.435 billion yuan), office stationery (1.607 billion yuan), and others [5] - The gross margins for writing tools, student stationery, and office stationery showed slight increases, while the traditional business faced revenue growth slowdowns due to external factors [5] - **Profitability**: - The company’s expense ratio increased slightly to 13.16% in Q2 2025, with a corresponding decrease in gross and net profit margins [6] - **Long-term Strategy**: - The company is committed to transformation and exploring new models, with a focus on enhancing efficiency and profitability through channel optimization and high-end product development [7] Investment Recommendations - The report adjusts the revenue forecast for 2025-2027, expecting revenues of 25.803 billion yuan, 28.383 billion yuan, and 31.222 billion yuan respectively, with net profits of 1.444 billion yuan, 1.601 billion yuan, and 1.774 billion yuan [9]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company experienced a revenue slowdown primarily due to online sales decline, influenced by a profit protection strategy. The adjustment of the Spobz strategy also contributed to the decrease in net profit [2][3] - The company is expanding its international presence while maintaining growth in established markets like Malaysia, Thailand, Vietnam, and Singapore, with plans to open stores in Sydney, Australia [3] Financial Performance - In H1 2025, the company achieved revenue of 11.566 billion yuan, a year-on-year increase of 1.73%, while net profit attributable to the parent company was 1.580 billion yuan, a decrease of 3.42% [2] - For Q2 2025, the company reported revenue of 5.379 billion yuan, a year-on-year growth of 3.59%, but net profit decreased by 13.92% to 645 million yuan [2] - The gross profit margin improved to 46.4% in H1 2025, up by 1.1 percentage points year-on-year, while the net profit margin decreased to 13.7%, down by 0.7 percentage points [5] Brand and Channel Analysis - The main brand's revenue in H1 2025 was 8.395 billion yuan, a decline of 5.86% year-on-year, while other brands saw significant growth [3] - Direct sales revenue increased by 17.2% to 2.9 billion yuan in H1 2025, while online sales revenue decreased by 4.8% [3] - The company opened 23 new JD Outlet stores, contributing to the growth of its other brands [4] Future Outlook - The company anticipates that online sales, overseas markets, and the Spobz strategy will be long-term growth drivers, with projections indicating that online sales could match offline sales in the next 3-5 years [7] - The revenue forecast for 2025-2027 has been adjusted downwards, with expected revenues of 21.13 billion yuan, 23.16 billion yuan, and 24.32 billion yuan respectively [7] Valuation Metrics - As of August 27, 2025, the closing price was 7.1 yuan, corresponding to a price-to-earnings ratio of 15 for 2025 [7]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's revenue and net profit for the first half of 2025 are projected to be 2.186 billion and 403 million CNY, respectively, showing year-on-year growth of 10.2% and 48.4% [2] - The improvement in the company's performance in 2024 is primarily attributed to cost and expense control, while the enrollment growth in 2025 is expected to accelerate revenue, particularly in the three-year program which grew by 4.5% and the one-to-two-year program which saw an impressive growth of 85% [2] - The company is expected to benefit from positive operating leverage, with adjusted net profit margin increasing by 5 percentage points [2] Summary by Sections Revenue and Enrollment - The company reported a significant increase in enrollment, with new registrations for the culinary technology and beauty sectors growing by 5.2% and 34.1%, respectively [4] - The total number of schools is 234, with a net increase of 1 school year-on-year [4] Financial Performance - The gross margin for the first half of 2025 is 57.3%, an increase of 4.3 percentage points year-on-year, driven by increased capacity utilization and reduced rental expenses [5] - The net profit margin for the first half of 2025 is 18.4%, reflecting a year-on-year increase of 4.7 percentage points, primarily due to a decrease in sales, management, and financial expense ratios [5] Future Outlook - Short-term expectations indicate strong autumn enrollment, with the potential for continued performance exceeding expectations throughout the year [7] - Mid-term projections suggest accelerated revenue growth in the coming years, particularly in culinary and automotive sectors, with ongoing improvements in profitability [7] - Long-term advantages include competitive employment outcomes and the ability to quickly adjust courses in response to market changes [7] Earnings Forecast - The company maintains revenue forecasts of 4.464 billion, 4.868 billion, and 5.390 billion CNY for 2025, 2026, and 2027, respectively [7] - The projected net profit for the same years is 801.94 million, 973.21 million, and 1.18293 billion CNY [7] - The earnings per share (EPS) forecast for 2025, 2026, and 2027 is 0.36, 0.44, and 0.54 CNY, respectively [7]

[Table_Title] 资产配置日报：有变化 证券研究报告|宏观点评报告 [Table_Date] 2025 年 08 月 27 日 | 国内市场表现 | | | | | | --- | --- | --- | --- | --- | | 指数 | 收盘 | 涨跌 | 幅度（%） | 五日走势 | | 上证指数 | 3800.35 | -68.03 | -1.76% | | | 沪深 300 指数 | 4386.13 | -66.46 | -1.49% | | | 中证可转债指数 | 476.94 | -13.82 | -2.82% | | | 7-10 年国开债指数 | 264.67 | -0.02 | -0.01% | | | 3-5 年隐含 AA+信用指数 | 189.70 | 0.05 | 0.02% | | 复盘与思考: 8 月 27 日，股市高位震荡，投资者内部观点或出现分化，大户、散户、主力日内先后止盈离场，机构资金成 主力买盘，各大股指在午后遭遇调整，上证指数尾盘跌幅扩大至 1.76%，勉强守住 3800。尽管股市表现不佳，但 债券现券表现也相对一般，T 与 TL 主力合约分别上涨 0.0 ...

证券研究报告|港股公司点评报告 公司公告与韩国潮流电商平台 Musinsa 成立合资企业，在合资企业中持有 40%股权，此次与 MUSINSA 合作 拓展中国市场，是公司在坚持'单聚焦、多品牌、全球化'战略的前提下，通过战略投资方式探索运动与时尚 的结合，更好地满足年轻消费者多元化的消费需求。 [Table_Date] 2025 年 08 月 27 日 [Table_Title] 主品牌批发承压，其他品牌维持高增 [Table_Title2] 安踏体育(2020.HK) | 评级： [Table_DataInfo] | 买入 | 股票代码： | 2020 | | --- | --- | --- | --- | | 上次评级： | 买入 | 52 周最高价/最低价(港元)： | 106.3/69.4 | | 目标价格(港元)： | | 总市值(亿港元) | 2,852.13 | | 最新收盘价(港元)： | 101.6 | 自由流通市值(亿港元) | 2,852.13 | | | | 自由流通股数(百万) | 2,807.21 | [Table_Summary] 事件概述 2025H1 公司实现收入/经调整归母 ...

Investment Rating - The investment rating for the company is "Buy" [3] Core Views - The company has maintained steady growth in its small molecule business, with new businesses expected to sustain rapid growth in the second half of 2025 [2] - In the first half of 2025, the company achieved revenue of 3.188 billion yuan, a year-on-year increase of 18.2%, and a net profit attributable to shareholders of 617 million yuan, up 23.7% year-on-year [1][2] Financial Performance - In the first half of 2025, the small molecule API business generated revenue of 2.43 billion yuan, a year-on-year increase of 10.6%, indicating stable growth [2] - The emerging business segment achieved revenue of 756 million yuan in the first half of 2025, a significant year-on-year increase of 51.2% [2] - The company has a total order backlog of 1.088 billion USD, with emerging business orders growing over 40% year-on-year, laying a solid foundation for future performance [2] - The chemical macromolecule CDMO segment saw revenue of 379 million yuan in the first half of 2025, a year-on-year increase of over 130% [7] - The biopharmaceutical CDMO segment generated revenue of 90 million yuan in the first half of 2025, a year-on-year increase of 70.74% [8] Future Outlook - The company is expected to continue strengthening its capabilities in small molecule "intermediates + APIs + formulations" integrated services, while also enhancing its presence in synthetic and biological macromolecule sectors [9] - Revenue forecasts for 2025-2027 have been adjusted slightly upward, with expected revenues of 6.659 billion yuan, 7.753 billion yuan, and 8.888 billion yuan respectively [9] - The earnings per share (EPS) estimates for 2025-2027 have been revised to 3.36 yuan, 3.82 yuan, and 4.27 yuan respectively [9]

证券研究报告|公司点评报告 [Table_Date] 2025 年 08 月 27 日 [Table_Title] 药品零售业务承压，区域深耕与新零售布局成 效显著 [Table_Title2] 老百姓(603883) [Table_Summary] 事件概述 2025H1 公司实现营收 107.7 亿元（yoy-1.5%），归母净利润 4.0 亿元（yoy -20.9% ），扣非 归母净利 润 3.8 亿 元（yoy - 20.9%）。单 Q2 营收 53.4 亿元（yoy-1.1%），归母净利润 1.5 亿 元（yoy-18.9%），扣非归母净利润 1.4 亿元（yoy-19.6%）。 盈利能力方面，2025H1 公司毛利率 33.1%（-1.2pcts），下滑系 新零售业务销售占比增加，归母净利率 3.7%（-0.9pcts），扣 非归母净利率 3.5%（-0.9pcts）；单 Q2 毛利率 31.9%（- 1.5pcts），归母净利率 2.8%（-0.6pcts），扣非归母净利率 2.6 （-0.6pcts）。 费用率方面，2025H1 公司销售费用率 21.9%（+0.1pcts），管理 费用率 4 ...

Investment Rating - The investment rating for the company is "Buy" [4] Core Views - The company is expected to achieve revenue of 11.51 billion yuan in H1 2025, representing a year-over-year growth of 9.12%, with a net profit attributable to the parent company of 2.05 billion yuan, showing a slight increase of 0.1% year-over-year [1] - The company is focusing on expanding its core business in refractive and optical services while enhancing its overseas operations, particularly in Europe and Southeast Asia, which contributed to 1.52 billion yuan in revenue, a year-over-year increase of 16.5% [3][8] - The implementation of AI diagnostic technology and the expansion into lower-tier markets are expected to drive long-term growth [8] Financial Performance - In H1 2025, the company reported a gross margin of 48.6%, a decrease of 0.9 percentage points, and a net profit margin of 17.8%, down by 1.6 percentage points [2] - The company’s total outpatient visits reached 9.248 million, an increase of 16.5% year-over-year, while the number of surgeries performed was 879,000, reflecting a growth of 7.6% [1] - For Q2 2025, the company achieved revenue of 5.48 billion yuan, a year-over-year increase of 2.5%, with a net profit of 1 billion yuan, down 13% year-over-year [1] Business Segmentation - The refractive project generated revenue of 4.62 billion yuan in H1 2025, accounting for 40.1% of total revenue, with a gross margin of 56.1% [4] - The optical service project reported revenue of 2.72 billion yuan, representing 23.6% of total revenue, while the cataract project generated 780 million yuan, accounting for 15.5% [4][7] - The company operates 355 domestic hospitals and 240 outpatient departments, along with 169 overseas eye centers and clinics [3] Cost Control and Efficiency - The company has effectively reduced its expense ratio to 24.5%, down by 2.1 percentage points, with a sales expense ratio of 9.1%, reflecting a shift to digital marketing [3] - Research and development expenses accounted for 1.3% of total revenue, indicating a focus on digital transformation [3] Future Projections - The company forecasts revenues of 23.43 billion yuan, 25.96 billion yuan, and 28.60 billion yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 11.7%, 10.8%, and 10.2% [8][10] - Net profit is projected to reach 4.07 billion yuan, 4.65 billion yuan, and 5.36 billion yuan for the same years, with growth rates of 14.5%, 14.2%, and 15.2% [8][10]